Last reviewed · How we verify

Metamizole and Ibuprofen

University Hospital, Basel, Switzerland · FDA-approved active Small molecule

Metamizole and ibuprofen are nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing pain, inflammation, and fever.

This is a fixed-dose combination of two nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX) enzymes to reduce pain, inflammation, and fever. Used for Acute pain management, Postoperative pain.

At a glance

Generic nameMetamizole and Ibuprofen
SponsorUniversity Hospital, Basel, Switzerland
Drug classNonsteroidal anti-inflammatory drug (NSAID) combination
TargetCyclooxygenase (COX-1 and COX-2)
ModalitySmall molecule
Therapeutic areaPain Management / Rheumatology
PhaseFDA-approved

Mechanism of action

Metamizole (dipyrone) is a pyrazolone NSAID that inhibits COX-1 and COX-2 enzymes, reducing prostaglandin production and providing analgesic and antipyretic effects. Ibuprofen is a propionic acid NSAID with similar COX inhibition. This combination leverages both agents' anti-inflammatory and analgesic properties for enhanced pain relief.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: